The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | The need to improve the quality of life of patients with AML undergoing alloSCT
Charles Craddock, CBE, FRCP(UK), FRCPath, DPhil, University of Birmingham, Birmingham, UK, discusses common post-transplant complications, as well as areas of unmet need for patients with acute myeloid leukemia (AML) undergoing allogeneic stem cell transplant (alloSCT). He highlights that quality of life (QoL) post-transplant needs greater consideration, that more research is required to optimize the prevention and treatment of graft-versus-host disease (GvHD), and that investigation of strategies to mitigate the psychological morbidity associated with the treatment is required to improve patient’s QoL. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Novartis: Consultancy; Abbvie: Consultancy, Research Funding; Celgene: Consultancy, Research Funding; JAZZ: Consultancy, Research Funding; Daiichi-Sankyo: Consultancy.
